Natco Pharma Ltd share price logo

Natco Pharma Ltd Share Price

(NATCOPHARM)

Small Cap

Healthcare Sector

₹798.75▲2.92%

as on 04:01PM, 28 Mar 2025

bell
The current prices are delayed by 15 mins, login to check live prices.

Natco Pharma Performance

  • Day's Low

    Day's High

    ₹795
    Day's Price Range
    ₹834.95

  • 52 Week's Low

    52 Week's High

    ₹757.05
    52-Week Price Range
    ₹1,639
1 Month Return+ 0.39 %
3 Month Return-42.42 %
1 Year Return-17.97 %
Previous Close₹822.75
Open₹822.85
Volume6.51L
Upper Circuit₹905.00
Lower Circuit₹740.50
Market Cap₹14,306.40Cr

Natco Pharma Fundamentals

P/E Ratio

7.67

PEG Ratio

0.23

Market Cap

₹14,306.40 Cr

P/B Ratio

3.05

EPS

77.56

Dividend Yield

1

Sector

Pharmaceuticals

ROE

25.38

Natco Pharma Analyst Rating

based on 12 analysts

HOLD

45.45%

Buy

18.18%

Hold

36.36%

Sell

Based on 12 analysts offering long term price targets for Natco Pharma. An average target of ₹1099.33

Source: S&P Global Market Intelligence

Natco Pharma Share analysis

Natco Pharma price forecast by 12 analysts

Upside of37.63%

High

₹1675

Target

₹1099.33

Low

₹710

Natco Pharma target price ₹1099.33, a slight upside of 37.63% compared to current price of ₹798.75. According to 12 analysts rating.

Source: S&P Global Market Intelligence

Key events for Natco Pharma Ltd

  • Natco Pharma Targets ₹2000 Cr Profit Amid Challenges - 30 Mar, 2025

    Natco Pharma aims for ₹1,800 to ₹2,000 crore PAT in FY25 and FY26 despite a 37.41% revenue decline in Q3FY25. The company plans to expand globally and launch key oncology products, while facing price erosion in Revlimid. Recent trading saw a 3% drop in share price.

  • Delhi HC Halts Natco Pharma's Risdiplam Launch - 26 Mar, 2025

    The Delhi High Court has instructed Natco Pharma to pause the launch of its generic Risdiplam until April 2 due to a patent dispute with Roche.

  • Delhi HC Clears Path for Natco's Generic Risdiplam - 25 Mar, 2025

    The Delhi High Court's ruling permits Natco Pharma to produce a generic version of Risdiplam, significantly lowering treatment costs for spinal muscular atrophy in India.

  • Natco Pharma Ltd Experiences Mixed Performance - 07 Mar, 2025

    Natco Pharma Ltd is up 0.06% today, marking its fifth consecutive session of gains. However, the stock has declined 18.68% over the past year and 35.76% in the last month, underperforming compared to the NIFTY and Nifty Pharma indices.

Insights on Natco Pharma Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 26.12% to 26.87% in Dec 2024 quarter

  • imgPOSITIVE IMPACT

    FII Holding Up

    img

    Foreign Institutions have increased holdings from 17.51% to 17.94% in Dec 2024 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Divis Laboratories Ltd has given 61.9% return, outperforming this stock by 79.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.2% return, outperforming this stock by 125.6%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 49.62% of holdings in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 2.37% to 1.92% in Dec 2024 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, NATCOPHARM stock has moved down by -42.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 677.3 Cr → 133.0 Cr (in ₹), with an average decrease of 80.4% per quarter

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 1.43K Cr → 651.1 Cr (in ₹), with an average decrease of 54.6% per quarter

Natco Pharma Financials

Value in ₹ crore
DetailsQ'4 23Q'1 24Q'2 24Q'3 24Q'4 24
Revenue₹758.60Cr (-)₹1,068.30Cr (↑40.83%)₹1,362.60Cr (↑27.55%)₹1,371.10Cr (↑0.62%)₹474.80Cr (↓65.37%)
Net Income₹212.70Cr (-)₹386.30Cr (↑81.62%)₹668.50Cr (↑73.05%)₹676.50Cr (↑1.20%)₹132.40Cr (↓80.43%)
Net Profit Margin28.04% (-)36.16% (↑28.96%)49.06% (↑35.67%)49.34% (↑0.57%)27.89% (↓43.47%)
Value in ₹ crore
Details2021202220232024
Total Assets₹4,817.40Cr (-)₹5,105.60Cr (↑5.98%)₹5,564.40Cr (↑8.99%)₹6,762.70Cr (↑21.54%)
Total Liabilities₹726.30Cr (-)₹913.70Cr (↑25.80%)₹862.40Cr (↓5.61%)₹1,170.40Cr (↑35.71%)
Value in ₹ crore
Details20202021202220232024
Operating Cash Flow₹422.50Cr (-)₹183.50Cr (↓56.57%)₹57.70Cr (↓68.56%)₹784.40Cr (↑1,259.45%)₹1,196.40Cr (↑52.52%)

Natco Pharma Index Inclusions

Nifty Small 100

₹16,095.70

-0.15 (▲-24.15%)

Nifty 500

₹21,339.55

-0.32 (▲-68.4%)

BSE 500

₹33,579.22

-0.39 (▲-132.39%)

NIFTY PHARMA

₹21,137.45

-0.65 (▲-137.7%)

S&P BSE 250 SmallCap

₹6,039.25

-0.45 (▲-27.45%)

S&P BSE 400 MidSmallCap

₹10,772.07

-0.52 (▲-56.71%)

Nifty Smallcap 250

₹15,104.05

-0.05 (▲-7.6%)

Nifty Smallcap 50

₹7,724.65

-0.15 (▲-11.25%)

S&P BSE SmallCap Select

₹6,954.89

0.04 (▲2.86%)

Nifty MidSmallcap 400

₹17,677.95

-0.2 (▲-36.15%)

BSE Small-Cap

₹46,638.13

-0.35 (▲-165.52%)

BSE Healthcare

₹41,421.50

-0.12 (▲-48.19%)

S&P BSE AllCap

₹10,471.31

0.68 (▲71.07%)

Natco Pharma Shareholding Pattern

InvestorsHoldings %FY Quarter3M change
Promoter Holdings
49.62%
0.00
Foreign Institutions
17.94%
2.44
Mutual Funds
1.92%
-19.02
Retail Investors
26.87%
2.88
Others
3.66%
-16.61

Natco Pharma Key Indicators

Details20202021202220232024
Earning Per Share (₹)25.1724.249.3239.1977.56
Details20202021202220232024
Return On Equity %12.777.782.5414.3325.38
Details20202021202220232024
Return On Assets %9.929.153.3312.8520.53
Details20202021202220232024
Book Value Per Share (₹)207.34225.84233.62267.06326.99

Natco Pharma Valuation

Natco Pharma in the last 5 years

  • Overview

  • Trends

Lowest (7.40x)

February 28, 2025

Today (7.67x)

March 28, 2025

Industry (53.18x)

March 28, 2025

Highest (90.32x)

April 6, 2022

LowHigh

Natco Pharma Earnings and Dividends

  • Natco Pharma Ltd Earnings Results

    Natco Pharma Ltd’s net profit fell -37.47% since last year same period to ₹133Cr in the Q3 2024-2025. On a quarterly growth basis, Natco Pharma Ltd has generated -80.36% fall in its net profits since last 3-months.

    Read More about Earnings Results

  • Natco Pharma Ltd Dividends February,2025

    In the quarter ending December 2024, Natco Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.91%.

    Read More about Dividends

Natco Pharma Technicals Summary

Bearish

Neutral

Bullish

Bearish

Natco Pharma Ltd is currently in a Bearish trading position according to technical analysis indicators.

More on Technical Analysis

Natco Pharma Peer Comparison

Company
Analyst ViewMarket Cap5 Year CAGRDebt to Asset RatioNet ProfitYearly Revenue
Natco Pharma Ltd
Natco Pharma Ltd
HOLD₹14,306.40 Cr11.6%0.54₹1,388 Cr₹3,998 Cr
Sanofi India Ltd
Sanofi India Ltd
BUY₹13,185.60 Cr-1.69%0.52₹602 Cr₹2,851 Cr
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd
BUY₹67,998.18 Cr36.18%0.56₹3,168 Cr₹29,001 Cr
Zydus Lifesciences Ltd
Zydus Lifesciences Ltd
HOLD₹89,192.58 Cr46.33%0.64₹3,854 Cr₹19,547 Cr
Abbott India Ltd
Abbott India Ltd
BUY₹65,281.17 Cr19.76%0.53NANA
See all

About Natco Pharma

Natco Pharma Limited is an international, RD focused pharmaceutical company that specialises in the development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). Natco sells products in over 40 countries, and provides contract manufacturing services for other pharmaceutical companies. The company was originally founded in 1981, and has since enjoyed significant growth, launching a variety of products and earning a number of milestones such as a compulsory license from Bayer for its patent protected anticancer drug Nexavar in 2012, and various first-to-market generic drugs including HEPCINAT (generic Sofosbuvir) and Epclusa (a single tablet regimen for the treatment of genotypes 2 and 3 chronic hepatitis C virus HCV infection). In 2021, Natco had 8 launches in the domestic market and acquired Dash Pharmaceuticals LLC in the US. Natco has 8 international subsidiaries, including the Philippines, Australia, Brazil and the US, constantly achieving the first generic to market for a variety of drugs. Natco's ambition for growth looks set to continue in 2022, with a number of new launches planned.

Revenue: ₹474.80Cr as on December 2024 (Q4 24)
Net Profit: ₹132.40Cr as on December 2024 (Q4 24)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
OrganisationNatco Pharma
HeadquartersHyderabad
IndustryPharmaceuticals
E-voting on sharesClick here to vote

FAQs on Natco Pharma Ltd

What is Natco Pharma Ltd price today?

Natco Pharma Ltd share price today stands at ₹798.75, Open: ₹822.85, Previous Close: ₹822.75, High: ₹834.95, Low: ₹795, 52 Week High: ₹1639, 52 Week Low: ₹757.05.

How to Buy Natco Pharma Ltd Share in India?

  • Get a PAN card
  • Open a Demat account
  • Open a Trading account
  • Link your Demat account to your Trading account
  • Fund your Trading account
  • Place an order to buy Natco Pharma Ltd shares

What are today's traded volumes of Natco Pharma Ltd?

Today's traded volume of Natco Pharma Ltd(NATCOPHARM) is 6.51L.

What is today's market capitalisation of Natco Pharma Ltd?

Today's market capitalisation of Natco Pharma Ltd(NATCOPHARM) is ₹14306.4Cr.

What is the 52 Week High and Low Range of Natco Pharma Ltd?

Natco Pharma Ltd (NATCOPHARM)
Price
52 Week High
₹1639
52 Week Low
₹757.05

How much percentage Natco Pharma Ltd is down from its 52 Week High?

Natco Pharma Ltd (NATCOPHARM) share price is ₹798.75. It is down -51.27% from its 52 Week High price of ₹1639

How much percentage Natco Pharma Ltd is up from its 52 Week low?

Natco Pharma Ltd (NATCOPHARM) share price is ₹798.75. It is up 5.51% from its 52 Week Low price of ₹757.05